摘要
卵巢癌是妇科恶性肿瘤致死率最高的肿瘤。肿瘤细胞减灭术辅以术后铂类为主的联合化疗是目前公认的卵巢癌标准治疗方案。但对于就诊时已属晚期且伴发高危疾病，无法直接手术的患者，术前的新辅助化疗（ Neoadjuvant chemotherapy ，NACT）的应用显示出了优越性，并得到了临床医生的肯定且已应用于晚期恶性肿瘤的治疗中。值得探讨的是：哪些患者在初次治疗时宜选用新辅助化疗，而不是直接行肿瘤细胞减灭术。本文对近年来的相关研究进行了归纳总结，希望对临床医生的决策有所帮助。
Ovarian cancer is the highest death rate of gynecologic malignant tumor. Currently, people rec- ognize standard treatment for ovarian cancer was that reduction - Tumor cells of platinum based chemotherapy af- ter surgery. But for those patients who have developed into advanced cancer that cannot be operated the surgeries directly, the application of preoperative Neoadjuvant chemotherapy （NACT） does have the superiority, which is recognized by the majority of clinical doctors, and has been widely used in the treatment of advanced malignant tumor. It is worthy to discussing which part of patients should choose the initial treatment of Neoadjuvant chemo- therapy,rather than a direct treatment of destroying tumor cells. This article is summarizing the empirical cases based on related research,in order to help clinicians to make a decision on the treatment of ovarian cancer.
出处
《实用肿瘤学杂志》
CAS
2014年第6期553-556,共4页
Practical Oncology Journal
关键词
晚期卵巢癌
新辅助化疗
评估
筛选标准
Advanced ovarian cancer
Neoadjuvant chemotherapy
Assessment
Screening criteria
